Leukemic transformation in myeloproliferative neoplasms (MPN), also referred to as “blast-
phase MPN”, is the most feared disease complication, with incidence estimates of 1–4% for …

The primary objective of treatment in myelofibrosis (MF) is prolongation of life, which is
currently accomplished only by allogeneic hematopoietic stem cell transplantation (AHSCT) …

Janus kinase (JAK) 2 inhibitors are now part of the therapeutic armamentarium for primary
and secondary myelofibrosis (MF). Patients with MF endure shortened survival and poor …

New options for medical therapy and risk scoring systems containing molecular data are
leading to increased complexity in the management of patients with myelofibrosis. To inform …

The number of patients with myelofibrosis (MF) undergoing an allogeneic hemopoietic stem
cell transplantation (HSCT) is increasing: in the analysis of the European Group for Blood …

Abstract Disease Overview Primary myelofibrosis (PMF) is a myeloproliferative neoplasm
(MPN) characterized by stem cell‐derived clonal myeloproliferation that is often but not …

Despite the approval of Janus kinase inhibitors and novel agents for patients with
myelofibrosis (MF), disease-modifying responses remain limited, and hematopoietic stem …

Hematopoietic cell transplantation (HCT) is a curative approach for myelofibrosis patients,
but relapse is a major cause of treatment failure. We investigated the effect of donor …

Allogeneic hematopoietic stem cell transplantation (alloHSCT) remains the only curative
treatment for myelofibrosis (MF). Relapse occurs in 10–30% and remains a major factor for …

Myelofibrosis (MF) is a clonal myeloproliferative neoplasm characterized by inflammation,
marrow fibrosis, and an inherent risk of blastic transformation. Hematopoietic allogeneic …